<DOC>
	<DOCNO>NCT02796677</DOCNO>
	<brief_summary>This multiple dose , randomize , parallel , double-blind , double-dummy , multicenter multinational Phase III study determine efficacy safety Aclidinium bromide 400μg/Formoterol Fumarate ( AB/FF ) 12 μg compare individual component TIO ( Tiotropium ) 18 μg administer patient stable chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>AMPLIFY - D6571C00001 Duaklir USA Phase III Study</brief_title>
	<detailed_description>This study conduct assess bronchodilator efficacy safety well effect health relate quality life AB/FF 400/12 μg compare individual component ( AB 400 μg FF 12 μg ) COPD patient . The trial duration 24 week allow assessment effect symptom improvement combine treatment versus individual component well long term bronchodilation comparison AB 400 μg TIO 18 μg minimize risk COPD exacerbation current former smoker , age ≥40 symptomatic COPD patient .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Adult male nonpregnant , nonlactating female patient age ≥40 . Patients diagnosis moderate severe stable COPD : postbronchodilator FEV1 &lt; 80 % predict normal postbronchodilator FEV1/FVC &lt; 70 % Screening Visit . Symptomatic patient CAT score ≥10 Screening Randomization visit ( Visits 1 2 ) . Current formersmokers , smoke history ≥ 10 packyears . Patients able perform acceptable repeatable pulmonary function test FEV1 accord American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) 2005 criterion Visit 1 . Patients eligible able participate study sign Informed Consent Form prior initiation studyrelated procedure . Involvement plan and/or conduct study ( applies AstraZeneca staff and/or site staff ) , patient employ relative employee site sponsor . Previous randomization present study D6571C00001 . Patients predominant asthma . Any respiratory tract infection ( include upper respiratory tract ) COPD exacerbation ( include mild COPD exacerbation ) within 6 week prior screen runin period . Patients hospitalize COPD exacerbation ( emergency room visit longer 24 hour consider hospitalization ) within 3 month prior Screening Visit . Clinically significant respiratory condition COPD . Patients Investigator 's opinion may need start pulmonary rehabilitation program study and/or patient started/finished within 3 month prior Screening . Use longterm oxygen therapy ( ≥ 15 hours/day ) . Patients maintain regular day/night , waking/sleeping cycle include night shift worker . Clinically significant cardiovascular condition . Patients uncontrolled Type I Type II diabetes , uncontrolled hypoor hyperthyroidism , hypokalaemia , hyperadrenergic state , uncontrolled hypertension . Patients history long QT syndrome whose QTc ( calculate accord Fridericia 's Formula QTc=QT/RR1/3 ) &gt; 470 m indicate centralised reading report assess Screening . Patients clinically significant abnormality laboratory test , ECG parameter ( QTc ) physical examination Screening Visit might comprise patient safety . Patient know noncontrolled history infection human immunodeficiency virus and/or active hepatitis . Patient history hypersensitivity reaction inhale medication component thereof , include paradoxical bronchospasm . Patients know narrowangle glaucoma , symptomatic bladder neck obstruction , acute urinary retention symptomatic nonstable prostate hypertrophy . History malignancy organ system ( include lung cancer ) , treat untreated , within past 5 year basal squamous cell skin cancer . Patients serious uncontrolled physical mental dysfunction . Patients history ( within 2 year prior screen ) drug and/or alcohol abuse may prevent study compliance base Investigator judgment . Patients unlikely cooperative comply study procedure . Patients treat investigational drug within 30 day ( 6 halflives , whichever long ) prior Screening . Patients intend use concomitant medication permit protocol undergone require washout period particular prohibit medication . Patients unable give consent , patient consent age guardianship , vulnerable patient . Patients demonstrate &lt; 80 % compliance electronic diary runin period .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Aclidinium bromide</keyword>
	<keyword>Formoterol fumarate</keyword>
	<keyword>Tiotropium</keyword>
	<keyword>Bronchodilation</keyword>
	<keyword>COPD</keyword>
</DOC>